Aprea Therapeutics, Inc. (APRE) is currently trading near its all-time low, and fell earlier this year due towards a failed late-stage cancer therapy study. In the near-term we could see a bounce off the 5.71 support line, before a fill towards 9.20. After hitting this fill, we should then expect a period of consolidation, and finally a last fill towards 25.50+ with expected good news in a 3-4 month time frame.
Note: this is not an investment idea, just my opinion.